US Nuclear Corp. Announces Annual 2020 Financial Results
US Nuclear Corp. (UCLE) reported its annual results for 2020, highlighting total sales revenue of $1,752,976, down from $3,540,387 in 2019. The company experienced a net loss of $3,538,103, attributed to COVID-19's impact. Operating expenses saw a significant reduction of 42%, totaling $2,558,553. Notably, demand for their DroneRAD products and water quality monitors has increased, with sales recovering in Q3 and Q4. The firm also acquired 40% of Grapheton, a startup focusing on advanced bioelectronics.
- Reduced operating expenses by 42% to $2,558,553.
- Sales recovery in Q3 ($484,318) and Q4 ($644,218) after COVID-19 challenges.
- Growing demand for innovative products like DroneRAD and water quality monitors.
- Acquisition of 40% of Grapheton, enhancing technology portfolio.
- Total sales revenue decreased by 50% from the previous year.
- Net loss of $3,538,103 due to COVID-19 impact.
- Equity loss of investment reached $818,611.
LOS ANGELES, CA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – US Nuclear Corp. (OTCQB: UCLE), a leading manufacturer of advanced radiation, chemical, and biological detection and UAV instrumentation, announced the annual results for the year ended December 31, 2020.
2020 Annual Highlights
- Total sales revenue of
$1,752,976 compared to$3,540,387 t he previous year - Net loss of
$3,538,103 due to impact of COVID-19 - Equity loss of investment
$818,611 - Amortization of debt discount
$462,963 - Total operating expenses reduced
42% to$2,558,553 as compared to$4,394,844 t he previous year
Robert Goldstein, CEO of US Nuclear Corp., commented:
“2020 was a challenging year for us due to COVID-19. The health and safety of our employees and their families was an urgent concern, and we took the necessary measures to ensure everyone stayed healthy. These measures included a temporary shut-down of one of our operating divisions, staggered and reduced work hours, and 14-day quarantine periods. Sales and production were especially slow in Q1 and Q2 due to the impact of COVID-19 on our company and customers, but started to recover in Q3 (
“On March 12, 2020 we closed a deal to purchase
“Despite a rough start to the year, we weathered the COVID-19 pandemic well, kept our employees safe, and are happy to announce that we are poised to continue growing and expanding as a sensor system developer and manufacturer.”
| US NUCLEAR CORP. AND SUBSIDIARIES | ||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||
| FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019 | ||||||||||||
| 2020 | 2019 | |||||||||||
| Sales | $ | 1,752,976 | $ | 3,540,387 | ||||||||
| Cost of sales | 1,278,469 | 1,605,447 | ||||||||||
| Gross profit | 474,507 | 1,934,940 | ||||||||||
| Operating expenses | ||||||||||||
| Consulting expense | 1,005,655 | 1,668,958 | ||||||||||
| Professional fees | 218,760 | 380,951 | ||||||||||
| Officer compensation | 220,000 | 896,000 | ||||||||||
| Payroll and related expense | 827,343 | 858,152 | ||||||||||
| General and administrative | 286,795 | 590,783 | ||||||||||
| Total operating expenses | 2,558,553 | 4,394,844 | ||||||||||
| Loss from operations | (2,084,046 | ) | (2,459,904 | ) | ||||||||
| Other income (expense) | ||||||||||||
| Writedown of investments | - | (508,000 | ) | |||||||||
| Interest expense | (45,860 | ) | (25,667 | ) | ||||||||
| Loss on issuance of convertible debenture | - | (183,978 | ) | |||||||||
| Change in value of derivative liability | (126,623 | ) | 53,813 | |||||||||
| Amortization of debt discount | (462,963 | ) | (37,037 | ) | ||||||||
| Equity loss in investment | (818,611 | ) | - | |||||||||
| Total other income (expense) | (1,454,057 | ) | (700,869 | ) | ||||||||
| Loss before provision for income taxes | (3,538,103 | ) | (3,160,773 | ) | ||||||||
| Provision for income taxes | - | - | ||||||||||
| Net loss | $ | (3,538,103 | ) | $ | (3,160,773 | ) | ||||||
| Weighted average shares outstanding - basic and diluted | 22,080,873 | 18,300,793 | ||||||||||
| Loss per shares - basic and diluted | $ | (0.16 | ) | $ | (0.17 | ) | ||||||
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.
Investors may find additional information regarding US Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website at www.usnuclearcorp.com
CONTACT:
US Nuclear Corp. (OTCQB: UCLE)
Robert I. Goldstein, President, CEO, and Chairman
Rachel Boulds, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com
FAQ
What is the total sales revenue reported by US Nuclear Corp (UCLE) for 2020?
What was the net loss for US Nuclear Corp (UCLE) in 2020?
How much did US Nuclear Corp (UCLE) reduce its operating expenses in 2020?
What were the sales figures for US Nuclear Corp (UCLE) in Q3 and Q4 of 2020?
What acquisition did US Nuclear Corp (UCLE) make in 2020?
